Short-lived effect of (Des-Tyr)-gamma-endorphin in schizophrenia.
J Volavka, K S Hui, B Anderson, Z Nemes, J O'Donnell, A Lajtha
Index: Psychiatry Res. 10(4) , 243-52, (1983)
Full Text: HTML
Abstract
Des-tyrosine-gamma-endorphin (DT gamma E) has been reported to alleviate symptoms of schizophrenia. Attempting to replicate those reports, we administered 1 mg of DT gamma E, i.m., for 8 consecutive days to nine patients meeting the DSM-III criteria for schizophrenia. Patients in this double-blind, crossover, and placebo-controlled study showed a statistically significant, but clinically modest improvement. The improvement was detectable during the first several days of the DT gamma E treatment; the symptoms then returned to baseline level in spite of continued doses of DT gamma E. Testing the metabolism of DT gamma E in the patients' plasma, we found a high rate of formation and of degradation, but the metabolic rates were not related to clinical symptoms.
Related Compounds
Related Articles:
1985-01-01
[Immunogenetics 22(4) , 309-14, (1985)]
Des-tyrosine-gamma-endorphin effects on morphine analgesia in mice.
1993-01-01
[Gen. Pharmacol. 24(1) , 83-8, (1993)]
1994-02-01
[J. Pharmacol. Exp. Ther. 268(2) , 1040-50, (1994)]
1988-09-01
[Br. J. Psychiatry 153 , 354-8, (1988)]
1986-10-01
[Int. Clin. Psychopharmacol. 1(4) , 303-13, (1986)]